“
TL;DR
The study found that mesalamine treatment was associated with significant improvement in multiple clinical symptoms, including fussiness, vomiting, and changes in stool consistency.
JPGN Reports · 2 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The study found that mesalamine treatment was associated with significant improvement in multiple clinical symptoms, including fussiness, vomiting, and changes in stool consistency.
A retrospective chart review identified 65 infants with severe refractory FPIAP from a pool of 580 diagnosed patients. Infants were <12 months old, had persistent severe symptoms despite >2 weeks on elemental formula, and underwent endoscopic evaluation. The mesalamine group also had a lower incidence of failure to thrive and fewer problems when transitioning to cow's or soy milk. Limitations include the retrospective design, reliance on parental symptom reports, and lack of randomization. The findings suggest mesalamine may be a safe and effective adjunctive therapy for infants with severe FPIAP unresponsive to standard dietary management.